We are thrilled to announce that InnoSer, as an innovative preclinical contract research organization (CRO), will be actively participating in the upcoming AD/PD 2024 Conference taking place in Lisbon, Portugal on March 5-9, 2024.
The theme of AD/PD 2024 is striving for a better future for all those affected by neurodegenerative diseases. This prestigious event, dubbed the main event of the year in the field of neurodegenerative diseases, gathers leading experts from around the world to share the latest advancements in research, diagnosis, and treatments for Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative disorders.
At InnoSer, we are committed to advancing neurodegenerative disease research by providing a broad range of preclinical research services using cellular and animal neurodegenerative disease models. We are delighted to be able to share our latest developments with other experts in the neurodegenerative field at the prestigious AD/PD 2024 Conference.
InnoSer’s neurology study director Jolien Beeken, PhD, will present our complementary in vitro service offering: “At AD/PD 2024, we look forward to showcasing our novel data from our broad neurodegenerative disease platform featuring in vitro assays to help our customers accelerate the identification and validation of new drug targets. The newly introduced validated cellular models will enable efficient screening of disease-modifying candidate compounds for Alzheimer’s and Parkinson’s diseases prior to, or in conjunction to screening in our neurodegenerative disease animal models.”
AD/PD 2024 represents a unique opportunity to interact with our team, gain in-depth insights into our neurology service offering, and discuss potential collaborations that can drive progress in the field. We invite you to attend our poster presentation or meet the InnoSer study directors Jolien Beeken, PhD, and Thomas Vogels, PhD, together with our business development manager Charlotte Wuyts, MSc, at booth #22.
Poster Topic: Theme A: β-Amyloid Diseases / A02.m. Therapeutic Targets, Mechanisms for Treatment: Microglia
Poster nr #262: Preclinical Neuronal Models to Screen the Effectiveness of Drugs Directed to Slow Down Alzheimer’s and Parkinson’s Disease Progression
About InnoSer’s neurology research services:
Founded in 2012, InnoSer is an innovative and dynamic CRO supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well characterized and complementary in vitro and in vivo disease models in addition to general drug development services, providing valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds. In addition to nephrology, immuno-oncology and cardiometabolic disease, InnoSer is specialised in neurology disease modelling. Our neurology models include: Fmr1 (FMRP, FRX), Stxbp1 (autism, epilepsy), Eif2B (leukodystrophy), APP/PS1 (Alzheimer), 22q11, PS19 (P301S, tauopathy), MPTP M83 (alpha-synuclein), Seeding (tau, aSyn), ALS (TDP-43, SOD1), FTD (TDP43) APOE, and are combined with a portfolio of sensitive and translational behavioral tests.
Interested in seamlessly combining your in vitro and in vivo research?
Complimentary range of Alzheimer’s disease models and unique behavioural services.
Unique behavioral services using in vivo models (MPTP, 6-OHDA, GBA, LRKK2, and alpha-synuclein).